Like all testosterone replacement products, Axiron (testosterone underarm liquid) can potentially increase the risk of blood clots by thickening the blood, elevating blood pressure, and increasing the number of red blood cells. These blood clots usually form in the legs, but they can break loose and get trapped in vital organs, causing a life-threatening heart attack, stroke, pulmonary embolism, or other severe side effect.
What is Axiron?
Axiron, a testosterone treatment product manufactured by Eli Lilly & Co., is an underarm liquid that delivers testosterone through transdermal absorption. It is marketed to treat symptoms of low testosterone (“Low T”), including fatigue, depressed mood, sexual dysfunction, osteoporosis, and more.
In 2011, over 5.3 million prescriptions were written for testosterone treatment products like Axiron. However, only 50% of patients actually had the condition Axiron is approved to treat — hypogonadism, a serious hormonal deficiency below 300 ng/dL.
FDA Adds Heart Attack, Stroke Warnings to Testosterone Products
March 3, 2015 — In a Safety Communication, the FDA is asking manufacturers of testosterone replacement products to stop marketing them for the treatment of age-related “Low T,” add warnings about heart attacks and strokes, and start studying the long-term risks. Click here to read more.
Axiron and Cardiovascular Side Effects
- Blood clots
- Heart attack
- Pulmonary embolism
- Deep vein thrombosis (DVT)
- Venous thromboembolism (VTE)
- Abnormal heart rhythm
- Organ damage
What is the problem?
Our lawyers are evaluating legal claims because we are concerned about studies suggesting that the life-threatening risks of Axiron could potentially outweigh any benefit, especially for men over 65 and/or people with heart disease.
Drug-makers are already facing several lawsuits accusing them of “disease mongering” — convincing millions of men who are losing testosterone to try a product with a lifetime commitment and serious side effects. These ads may also misleadingly suggest that hypogonadism is widespread.
FDA Safety Alert for Testosterone Therapy
The U.S. Food and Drug Administration (FDA) published a Drug Safety Communication for testosterone replacement therapy on January 31, 2014, in response to concerning data from two studies.
The announcement came just days after PLoS One published research on over 50,000 men, finding that testosterone could double the risk of heart attack for men over 65. Three months before that study was published, another study in the Journal of the American Medical Association indicated that testosterone may increase a man’s risk of heart attack, stroke, and death by 30%.